New drug aims to keep rare lymphoma in check after initial treatment
NCT ID NCT07347288
First seen Jan 20, 2026 · Last updated May 05, 2026 · Updated 15 times
Summary
This study tests the drug SHR2554 as a maintenance therapy for people with peripheral T-cell lymphoma (PTCL) who have responded to their first treatment. The goal is to see if taking this drug can help keep the cancer from coming back longer. About 30 adults whose cancer is in remission or partially shrunk will take SHR2554 and be monitored for side effects and how long they stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210000, China
Conditions
Explore the condition pages connected to this study.